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Abstract Variation in the risk and severity of many autoimmune diseases, malignancies and
infections is strongly associated with polymorphisms at the HLA class I loci. These genetic
associations provide a powerful opportunity for understanding the etiology of human disease. HLA
class I associations are often interpreted in the light of ‘protective’ or ‘detrimental’ CD8+ T cell
responses which are restricted by the host HLA class I allotype. However, given the diverse
receptors which are bound by HLA class I molecules, alternative interpretations are possible. As
well as binding T cell receptors on CD8+ T cells, HLA class I molecules are important ligands for
inhibitory and activating killer immunoglobulin-like receptors (KIRs) which are found on natural killer
cells and some T cells; for the CD94:NKG2 family of receptors also expressed mainly by NK cells
and for leukocyte immunoglobulin-like receptors (LILRs) on myeloid cells. The aim of this study is to
develop an immunogenetic approach for identifying and quantifying the relative contribution of
different receptor-ligand interactions to a given HLA class I disease association and then to use this
approach to investigate the immune interactions underlying HLA class I disease associations in
three viral infections: Human T cell Leukemia Virus type 1, Human Immunodeficiency Virus type 1
and Hepatitis C Virus as well as in the inflammatory condition Crohn’s disease.
Introduction
Genetic associations provide a powerful opportunity for understanding the etiology of human dis-
ease since, unlike most human observational studies, once linkage disequilibrium is corrected for,
associated genes can be assumed to be causal rather than simply correlative.
The HLA region is a well-known hotspot for disease associations: it comprises just 0.3% of the
genome yet contains 6.4% of the significant SNP associations in the EMBL-EBI genome wide associa-
tion study (GWAS) catalog (MacArthur et al., 2017). Multiple candidate gene and GWAS studies
have identified significant associations between polymorphisms in the classical HLA class I genes and
the risk and/or severity of infectious disease, a range of autoimmune conditions and a number of
forms of cancer (Matzaraki et al., 2017). A search of the literature yields over 2000 papers reporting
HLA class I disease associations. Some of the most striking odds of disease are seen with autoim-
mune conditions such as the association between ankylosing spondylitis and possession of HLA-B*27
(odds ratio >100) or between Behc¸et’s Disease and HLA-B*51 (accounts for 32–50% of cases)
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(Matzaraki et al., 2017; de Menthon et al., 2009). Amongst infectious pathogens, HIV-1 has some
of the best studied genetic associations: HLA-B*57 is strongly associated with reduced viral load and
slow progression of disease in multiple cohorts whilst HLA-B*35Px is associated with high viral load
and poor prognosis (Pereyra et al., 2010; Carrington and O’Brien, 2003; Martin et al., 2007;
Carrington et al., 1999; Kiepiela et al., 2004).
However, interpretation of HLA class I disease associations is problematic since the classical HLA
class I molecules (HLA-A, -B and –C), which bind cytosolic peptides (typically of length 8–11 amino
acids) have multiple functions. HLA class I molecules are the ligands for several different receptors
expressed by different immune cells including CD8+ T cells, NK cells and dendritic cells.
CD8+ T cells recognise HLA:peptide via their T cell receptor (TCR). TCR-HLA:peptide binding is
exquisitely specific and depends both on the HLA allele and the sequence of the bound peptide.
The affinity of an HLA class I molecule for a peptide is a significant determinant of the CD8+ T cell
response elicited by that peptide (Chen et al., 2000; Mu¨llbacher et al., 1999; Yewdell and Ben-
nink, 1999; Deng et al., 1997; Boggiano et al., 2005); it has been shown that 85% of epitopes
bind their HLA molecule with an affinity of 500 nM or stronger (Assarsson et al., 2007). However
the relationship between HLA binding and immunogenicity is nontrivial, 50–66% of peptides that
bind do not elicit a response (Lee et al., 2004; Hoof et al., 2010) and conversely cases where a
peptide has undetectable binding but still elicits a response have also been described (Lee et al.,
2004). A second crucial determinant of immunogenicity is binding of the HLA:peptide complex to
the T cell receptor. It has been established that peptide positions P4-8 are most likely to be in close
contact with the TCR (Rudolph et al., 2006; Garboczi et al., 1996; Calis et al., 2012). However,
which of these peptide positions are critical for a T cell’s ability to bind have not been comprehen-
sively mapped in humans; additionally non-contact positions can also impact on TCR specificity
(Hausmann et al., 1999). Most studies only investigate one or two HLA molecules; the residues
identified as important in these studies (for TCR recognition rather than HLA binding) include P4, 6
and 8 (Lee et al., 2004), P3, 5, 6 and 8 (Tynan et al., 2005), P3-5 (Wooldridge et al., 2010) and P3-
eLife digest When considering someone’s risk of disease, every person is different but some
similarities can be found when looking across populations. Some people are more likely to develop
a certain disease, while others are protected in some way. Part of this variation is explained by the
individual’s genes, while their lifestyle and environment are other factors.
Numerous studies have looked for associations between different versions of genes, known as
gene variants, and the occurrence of disease to identify who is at risk. There is one cluster of genes
called the HLA genes that is a well-known hotspot for disease associations. The HLA cluster is
named for the group of proteins it encodes, called the human leukocyte antigen (HLA) complex.
These cell-surface proteins regulate the immune system in humans. These proteins are present on
the surface of cells, and they help the immune system distinguish foreign invaders such as viruses
and bacteria from the body’s own cells. Variants in the HLA genes are associated with more than
100 diseases, including infectious diseases like HIV, autoimmune conditions such as multiple
sclerosis, and some cancers. However, while identifying which genetic variants are associated with
an increased or decreased risk of disease is relatively simple, understanding why those genetic
variants are associated with a particular disease is much harder.
Debebe et al. have developed a new method to find out why certain gene variants in the HLA
cluster are associated with disease in humans. They used this method to investigate known genetic
variants associated with three viral infections: HIV, hepatitis C, and human leukemia virus – and one
inflammatory disease: Crohn’s disease. Critically, Debebe et al. looked at the interactions between
different immune cells and the cell-surface proteins encoded by the HLA gene variants in different
cases of these diseases. In doing so, the analysis was able to identify which cells of the immune
system were responsible for the associations between gene variants and diseases.
In principle, this method could be applied to study any disease in any species. It could also be
used in classic gene association studies to test for false positive results and “passenger” mutations,
two common problems that beset sound interpretations from these studies.
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6 and 8 (Hausmann et al., 1999). A comprehensive study of murine data by the Kesmir group con-
vincingly identified P4-6 (Calis et al., 2013) but it is unclear how this translates to human HLA:pep-
tide as sparsity of data prevents a similar analysis in humans.
NK cells bind HLA class I molecules via two distinct groups of receptors, killer immunoglobulin-
like receptors (KIRs) and CD94:NKG2. KIRs are a family of inhibitory and activating receptors that
are expressed mainly on the surface of NK cells and also some T cells. KIRs recognise broad group-
ings of HLA class I molecules sharing structural motifs. For instance KIR2DL1 binds HLA-C molecules
with an asparagine at position 80 (designated the C2 group of alleles). Whereas KIR2DL3 binds
HLA-C molecules with a lysine at position 80 (designated the C1 group) (Trowsdale, 2001;
Moesta et al., 2008). Exceptions to these broad rules have been described (Sim et al., 2017). KIR
binding also shows some dependence on the HLA-bound peptide, particularly positions 7 and 8,
though this specificity is weak compared to that of the TCR (Fadda et al., 2010; Maenaka et al.,
1999a; Maenaka et al., 1999b; Boyington et al., 2000).
The second way in which NK cells (and to a lesser extent, T cells) survey HLA class I expression is
via the CD94:NKG2 family of receptors. Particularly interesting is the inhibitory CD94:NKG2A recep-
tor which ligates the monomorphic non-classical HLA-E loaded with peptide from the leader
sequence of HLA-A, -C and a subset of –B molecules (Braud et al., 1998; Lo´pez-Botet et al., 2000)
and which has been recently shown to play a key role in NK cell education (Horowitz et al., 2016).
Finally, HLA class I molecules are also the ligands for the leukocyte immunoglobulin-like receptors
(LILR) of which LILRB1 and LILRB2 are the best characterised. Different HLA allotypes bind LILRB1
and LILRB2 with varying affinity, this is particularly true for LILRB2 which shows considerable variation
across the HLA alleles (Jones et al., 2011). LILRB1 and LILRB2 are inhibitory receptors which are
expressed mainly on myeloid cells including dendritic cells and macrophages; signalling via LILR
affects the activation of these antigen presenting cells (Bashirova et al., 2014). To the best of our
knowledge the impact of HLA-bound peptide on LILR signalling has not been investigated.
As a result of these diverse functions of HLA class I molecules the biological mechanisms underly-
ing HLA associations with disease outcome are difficult to infer and contradictory interpretations of
the same associations are common. Consider, for example, HLA-B*57-associated protection in the
context of HIV-1 infection. It has been suggested that HLA-B*57 is protective because it preferen-
tially presents CD8+ T cell epitopes from the highly conserved Gag p24 protein which is less suscep-
tible to escape mutations (Borghans et al., 2007; Kiepiela et al., 2007; Miura et al., 2009) and that
T cell responses to Gag are specifically associated with a reduced HIV-1 viral load (Kiepiela et al.,
2007). Indeed, the association between B*57 and low viral load is widely cited as evidence that
CD8+ T cells are important in controlling HIV-1 (Boppana and Goepfert, 2018; Walker and McMi-
chael, 2012). However, it has also been argued (Flores-Villanueva et al., 2001) that HLA-B*57 is
protective because of its role as a KIR ligand (binding both the inhibitory receptor KIR3DL1 and the
activating receptor KIR3DS1); an argument which, though disputed (O’Brien et al., 2001), does
appear to be supported by subsequent studies (Martin et al., 2007; Martin et al., 2002;
Pelak et al., 2011). It has also been suggested that the unusually weak binding of HLA-B*57:01 for
LILRB2 contributes to control of HIV-1 viral load due to its reduced inhibitory regulation of dendritic
cells (Bashirova et al., 2014). Finally, recent papers have called for a re-evaluation of HLA class I clin-
ical associations, including HLA-B*57, taking into account the fact that HLA-B*57, by virtue of having
a methionine at position 21 provides peptides for HLA-E thus supplying CD94:NKG2A ligands
(Horowitz et al., 2016; Yunis et al., 2007). In short, the HLA-B*57 protective effect may be attribut-
able to CD8+ T cells, to inhibition of NK cells via KIR3DL1, to activation of NK cells via KIR3DS1, to
inhibition of NK cells via CD94:NKG2A and/or to reduced inhibition of DCs via LILRB2. Observa-
tional and in vitro studies to investigate the mechanism underlying the B57-protective effect have
yielded inconclusive results. The interpretation of observational studies are problematic since, for
example, a preponderance of polyfunctional CD8+ T cells in HLA-B*57+ elite controllers of HIV-1
may be because polyfunctional CD8+ T cells are responsible for elite control. But it is hard to rule
out the possibility that polyfunctionality is a consequence of low viral load. In vitro functional work is
also difficult to interpret, with CD8+ T cells, natural killer cells and DCs all playing a role depending
on the in vitro experimental conditions, with no obvious means to infer the relative importance of
these different factors in vivo.
The aim of this study is to develop an immunogenetic approach for identifying and quantifying
the relative contribution of different receptor-ligand interactions to a given HLA class I disease
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association. We applied this approach to investigate well-described associations between
single HLA class I alleles and disease in 3 viral infections: Human T cell Leukemia Virus type 1 (HTLV-
1), Human Immunodeficiency Virus type 1 (HIV-1) and Hepatitis C Virus (HCV) (Carrington and
O’Brien, 2003; Kim et al., 2011; Jeffery et al., 1999). We then extended the scope of this work by
using the method to investigate the association between the multi-gene ancestral MHC 8.1 haplo-
type and good prognosis in Crohn’s disease (Lee et al., 2017).
Results
Strategy
We focus on receptor-ligand pairs which are polymorphic and well-characterised. Specifically, we
investigate TCR-HLA:peptide, inhibitory KIR-HLA:peptide, activating KIR-HLA:peptide, LILRB1-HLA
and LILRB2-HLA. The strategy was first to develop a metric for quantifying the proximity or similarity
of HLA class I alleles in terms of their TCR binding (i.e. a metric in ‘CD8+ T cell recognition space’),
metrics for quantifying the proximity of HLA class I alleles in terms of their activating and inhibitory
KIR binding (i.e. distance metrics in ‘NK cell recognition space’) and metrics for quantifying the prox-
imity of HLA class I alleles in terms of their LILRB1 and LILRB2 binding (i.e. distance metrics in ‘DC
recognition space’). Next, for the HLA class I allele with the disease association of interest (hence-
forth the ‘index’ allele), the similarity to all other HLA class I alleles in terms of TCR binding, inhibi-
tory KIR binding (iKIR), activating KIR (aKIR), LILRB1 and LILRB2 binding was estimated. Multivariate
regression was used to quantify the association between similar HLA class I alleles and clinical out-
come. We hypothesised that, if an HLA class I disease association is attributable to CD8+ T cells then
other HLA class I alleles with similar TCR-HLA:peptide binding to the index allele would have similar
disease associations whereas HLA class I alleles with similar KIR-HLA:peptide and LILR-HLA binding
would show no disease associations. Conversely, if the HLA class I allele disease association is attrib-
utable to NK cells then HLA class I alleles that are near in KIR-HLA:peptide binding space but not
HLA class I alleles which are near in TCR-HLA:peptide binding space or LILR-HLA binding space
would be associated with disease. And similarly for LILR binding. Inclusion of combinations of dis-
tance metrics as predictors in the regression also allows us to quantify the relative contribution of
different receptor-ligand interactions and whether or not they behave independently in the case
where more than one interaction was identified as playing a role. Details of the distance metrics are
provided in the Methods, a brief, more intuitive, summary is provided below. Figure 1 illustrates the
approach.
A TCR similarity metric
To quantify the similarity between two alleles in terms of TCR-HLA:peptide binding we first identify
the 8-, 9-, 10- and 11-mer peptides from the proteome of interest predicted to bind each of the two
HLA alleles using the prediction software netMHCpan v4.0 (Nielsen et al., 2007; Jurtz et al., 2017).
For each of the predicted binders we then identify the amino acids at positions expected to impact
on TCR binding. This was taken to be positions 3–6 as they have been repeatedly identified as
important in TCR recognition (Lee et al., 2004; Hausmann et al., 1999; Tynan et al., 2005;
Wooldridge et al., 2010; Calis et al., 2013); we also included the anchor positions 2 and the termi-
nal position since different amino acid contacts with the HLA molecule may alter the conformation
and/or orientation of the presented peptide. The method is flexible and different amino acid posi-
tions (other than 3–6 and/or excluding anchor residues) can easily be considered. The fraction of
these 6 amino acid-long motifs (2, 3–6, terminal) that were shared between the alleles was then used
as a measure of the similarity between the two alleles. We denote this continuous variable ‘TCR.FS’
(TCR fraction shared); it takes values between one (100% shared motifs) and zero (no shared motifs).
As a basic test of the TCR.FS metric we investigated the hypothesis that the TCR.FS would be higher
between alleles of the same supertype than between alleles of different supertypes. This hypothesis
was strongly supported (p=310 7 Wilcoxon two tailed test, Appendix 2 Supplementary Results,
Appendix 4—figure 1).
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Index HLA allele to be 
inves!gated: HLA-A02:07 
(protec!ve in context of 
HTLV-1) 
HTLV-1-infected cohort 
ID outcome A1 A2 B1 B2 C1 C2 
Individual 1 CASE A1101 A2402 B0702 B0702 C0702 C0702 
Individual 2 CASE A0301 A3201 B1402 B0803 C0701 C0304 
…
       
Individual 1 has 4 unique alleles (marked with red dots in the preceding graph). The most similar to 
A02:07 in terms of TCR binding is C07:02 with TCR.FS=0.273. Individual 1 thus has a TCR.FS with 
A02:07 of 0.273. This is repeated for all individuals in the cohort and all 5 metrics.  
HTLV-1-infected cohort 
ID outcome A1 A2 B1 B2 C1 C2 TCR.FS iKIR.FS aKIR.FS LILRB1.S LILRB2.S 
Individual 1 CASE A1101 A2402 B0702 B0702 C0702 C0702 0.273 1 1 0.594 0.906 
Individual 2 CASE A0301 A3201 B1402 B0803 C0701 C0304 0.553 …    
…
             
Perform regressions 
1. Index only Outcome ~ A*02:07 + age +gender 
2. Index + TCR.FS Outcome ~ A*02:07 + TCR.FS + age +gender 
3. Index + iKIR.FS Outcome ~ A*02:07 + iKIR.FS + age +gender 
4. Index + aKIR.FS Outcome ~ A*02:07 + aKIR.FS + age +gender 
5. Index + LILRB1.S Outcome ~ A*02:07 + LILRB1.S + age +gender 
6. Index + LILRB2.S Outcome ~ A*02:07 + LILRB2.S + age +gender 
(i) (ii) 
(iii) 
(iv) 
(v) 
(vi) 
Similarity of each HLA allele to A02:07 in CD8+ T cell Recogni!on space 
 
Index allele 
A02:07 
Significantly 
protec!ve 
 
Distance in TCR space 
Distance in iKIR space 
Distance in LILRB1 space 
Alleles with similar TCR binding 
are also protec!ve  
Alleles with similar LILRB1 
binding are not protec!ve 
 
Alleles with similar iKIR binding 
are not protec!ve 
 
Interpreta!on 
Figure 1. Schematic of method. An overview of the method using the example given in Appendix 1 Supplementary Methods ‘Worked example of the
Fraction Shared’. More details can be found in the Materials and methods and Appendix 1 Supplementary Methods. (i) Consider the example of
investigating the mechanism underlying the association between HLA-A*02:07 and reduced risk of disease (HAM/TSP) in the context of HTLV-1
infection. (ii) Take the HTLV-I cohort and for each individual calculate their nearness to A*02:07 in ‘CD8 T cell recognition space’ (i.e. calculate TCR.FS).
(iii) The graph shows the similarity to A*02:07 (TCR.FS) for each HLA allele in the cohort ranked from most similar on the left to least similar on the right.
Individual 1 is homozygous at both their HLA-B and HLA-C loci so they have 4 unique alleles (A*11:01, A*24:02, B*07:02, C*07:02). We calculate the
similarity of A*02:07 to each of these HLA alleles, they are marked on the graph as red dots. The most similar allele to A*02:07 in terms of CD8
recognition carried by individual 1 is C*07:02 with a TCR.FS = 0.273. Individual 1 thus has a TCR.FS with A*02:07 of 0.273. (iv) This is repeated for all
individuals in the cohort and all 5 metrics and the cohort table completed. The table relates only to nearness to A*02:07 for the HTLV-1 proteome, for
Figure 1 continued on next page
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iKIR and aKIR similarity metrics
To quantify the similarity between two alleles in terms of inhibitory KIR-HLA:peptide and activating
KIR-HLA:peptide binding we first established whether the alleles contain the same iKIR or aKIR bind-
ing motif (based on positions 77 and 80) (Trowsdale, 2001; Moesta et al., 2008). The similarity
between two alleles that did not share a KIR binding motif was set to zero. For alleles that did share
a KIR binding motif the fraction of motifs shared (similarity) was calculated as for the TCR metric but
the peptide positions considered to affect KIR binding were taken to be 7 and 8 (Fadda et al.,
2010; Maenaka et al., 1999a; Maenaka et al., 1999b; Boyington et al., 2000); as for TCR.FS we
also included peptide anchor positions 2 and 9. We denote these continuous variables ‘iKIR.FS’ and
‘aKIR.FS’. As for TCR.FS, these metrics vary between one and zero.
LILRB1 and LILRB2 similarity metric
To quantify the similarity between two alleles in terms of LILRB1-HLA and LILRB2-HLA binding we
compared the strength of binding between LILRB1 (LILRB2 resp.) and each HLA allele
(Bashirova et al., 2014). We denote these continuous variables ‘LILRB1.S’ and ‘LILRB2.S’ (LILRB1
and LILRB2 similarity). Again, they take values between zero and one. Note, due to lack of data, the
measures of LILRB1 and LILRB2 similarity are peptide-independent.
Regressions
The similarity between the index allele and the alleles of each individual in the relevant cohort was
calculated using the five metrics. To ensure that near alleles were considered independent of the
index, the similarity metrics were set to zero if the individual carried the index allele. The metrics
were then included, along with the index allele, as an independent variable in a regression analysis
to identify determinants of clinical outcome.
HTLV-1 infection: interactions underlying protective and detrimental
alleles
We studied a case-control cohort of 392 HTLV-1-infected individuals from Kagoshima in Southern
Japan. 178 subjects were asymptomatic carriers of the virus, and 214 subjects were diagnosed with
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) according to World Health
Organisation criteria. There are well-documented associations between HLA-A*02, HLA-C*08 and
HLA-B*54 and outcome (Jeffery et al., 1999; Jeffery et al., 2000). HLA-A*02 and HLA-C*08 are
protective: they are associated with a reduced risk of HAM/TSP whilst HLA-B*54 is detrimental: it is
associated with an increased risk of HAM/TSP. There are also reported associations with proviral
load, but these associations suffer from poor robustness (next section) so we do not investigate
them further. We first identified which HLA alleles at the 4 digit level were driving these disease
associations. A*02:06 and A*02:07 are associated with a reduced risk of disease, C*08:01 was weakly
associated with a reduced risk of disease and B*54:01 was associated with an increased risk of dis-
ease (Appendix 3—table 1). To assess which immune interactions were responsible for these associ-
ations with HAM/TSP, for each of these 4 HLA alleles, we performed 5 regressions, one for each of
the similarity metrics (TCR.FS, aKIR.FS, iKIR.FS, LILRB1.S and LILRB2.S), in each case the index allele
(together with age and gender) were included as covariates. Results are given in Table 1. We found
that for each of the index HLA class I alleles considered, TCR.FS was strongly associated with risk of
Figure 1 continued
another index allele (or another proteome) the process will need to be repeated to complete the table (v) multiple regression is then performed on the
cohort. Each metric is included in turn as a predictor variable. To investigate the independence or relative importance of different predictors they
should be included in the regression model together (vi) Results of the regression are then interpreted. In this case the index A*02:07 is protective;
other HLA class I alleles with similar TCR-HLA:peptide binding to the index allele are also protective that is, TCR.FS is a significant (protective) predictor
of outcome; whereas HLA class I alleles with similar iKIR-HLA:peptide and LILRB1-HLA binding show no protective associations. Only three dimensions
are sketched; similarity in aKIR and LILRB2 binding-space are also computed (and near alleles were not protective). We conclude that A*02:07-
associated protection is most likely to be attributable to its TCR binding properties.
The online version of this article includes the following source data for figure 1:
Source data 1. Data underlying Figure 1.
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Table 1. Interactions underlying HLA class I disease associations in HTLV-1 infection.
Four HLA class I alleles are associated with disease (HAM/TSP) in HTLV-1 infection (model 1, index only). For each HLA allele we
sought to determine the underlying mechanism by performing 5 multivariate logistic regressions (model 2–6), one for each of the dis-
tance metrics. The coefficient (Coeff) and P value for the index allele and the nearby alleles (similarity metric) are recorded below. For
each of the index HLA alleles considered TCR.FS was associated with disease and in the same direction as the index allele; that is
when the index was protective alleles with similar TCR binding (high TCR.FS) were protective and when the index was detrimental
TCR.FS was detrimental (see row ‘TCR.FS’ in model 2, shaded). Furthermore, inclusion of TCR.FS in the multivariate analysis actually
strengthened the effect of the index allele in every case (compare the magnitude of the coefficient for index in model 1 and index in
model 2) indicating that removal of near alleles from the baseline made the ‘background’ alleles more dissimilar to the index. None of
the other metrics were significant for any of the index alleles considered. Coeff <0 indicates reduced risk of HAM/TSP (i.e. a protective
effect, ‘P’), Coeff >0 indicates increased risk of HAM/TSP (i.e. a detrimental effect, ‘D’). The odds ratio = exp(Coeff). The additional
covariates age and gender were included in the regressions. Significance codes: p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P values
are two tailed.
Index allele
Model Covariate A*02:06 A*02:07 C*08:01 B*54:01
1.
Index only
Index Coeff  0.55
P
 1.27
P
 0.52
P
0.96
D
P val 0.086

0.0079
**
0.19 0.0056
**
2.
Index + TCR.FS
Index Coeff  0.67  1.32  0.70 1.15
P val 0.042
*
0.0057
**
0.086

0.0014
**
TCR.FS Coeff  5.48
P
 2.40
P
 1.66
P
1.57
D
P val 0.00014
***
0.017
*
0.075

0.02
*
3.
Index + iKIR.FS
Index Coeff  0.55  1.26  0.72 +0.82
P val 0.08

0.009
**
0.083

0.02
*
iKIR.FS Coeff  0.43
P
 0.36
P
 1.23
P
 0.87
P
P val 0.51 0.63 0.12 0.11
4.
Index + aKIR.FS
Index Coeff  0.55  1.25  0.51 +0.83
P val 0.08

0.009
**
0.20 0.019
*
aKIR.FS Coeff  0.47
P
 0.41
P
0.18
D
 0.64
P
P val 0.48 0.60 0.70 0.13
5.
Index + LILRB1.S
Index Coeff  0.48  1.36  0.60 1.06
P val 0.15 0.008
**
0.16 0.005
**
LILRB1.S Coeff 0.65
D
 0.47
P
 0.49
P
0.92
D
P val 0.51 0.61 0.61 0.47
6.
Index + LILRB2.S
Index Coeff  0.49  1.13  0.61 0.96
P val 0.15 0.029 0.14 0.009
**
LILRB2.S Coeff 0.45
D
0.84
D
 0.73
P
 0.05
P
P val 0.63 0.51 0.50 0.96
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disease and in the same direction as the index allele i.e. possession of alleles with similar TCR bind-
ing to A*02:06, A*02:07 and C*08:01 are associated with a large decrease in the risk of disease
whilst possession of alleles near B*54:01 in TCR binding space is associated with a significant
increase in the risk of disease. In every case inclusion of TCR.FS in the multivariate analysis strength-
ened the effect of the index allele (i.e. increased the magnitude of the coefficient) indicating that
removal of near alleles from the baseline made the ‘background’ alleles more dissimilar to the index.
None of the other metrics were significant for any of the index alleles considered. We conclude that
for all 4 HLA class I alleles studied in HTLV-1 infection the protection/susceptibility associated with
those alleles is best explained by their TCR binding properties and therefore is most likely to be
attributable to CD8+ T cells.
HTLV-1 infection: what determines the risk of disease across all alleles?
Having investigated the ‘extreme case’ alleles that are most strongly associated with protection or
susceptibility in HTLV-1 infection we next sought to analyse the larger group of ‘average’ alleles
associated with intermediate risk of HAM/TSP. Here we define an ‘average allele’ as one that is not
significantly associated with outcome (p>0.05), is represented in the cohort at a sufficient frequency
(N > 15) and has sufficient near alleles to permit an analysis (N > 15 with 50% or more similarity).
It is possible that there is no meaning in the rank order of protection associated with different
average alleles. That is, it is possible that, other than the extremes, most HLA class I alleles confer
very similar levels of protection and the order of protection that we see is simply a function of the
particular cohort studied (and that analysis of another cohort would yield a different rank order).
However, a subsampling strategy revealed that this was not the case and that rank order of interme-
diate alleles was robust and significantly more informative than random when considering the risk of
disease but not when considering proviral load (Appendix 2 Supplementary Results ‘Are average
HLA class I associations robust’, Appendix 4—figure 2). Consequently, it is meaningful to analyse
the impact of average alleles on risk of HAM/TSP but not on proviral load.
For each HLA class I allele in the HTLV-1 cohort that was sufficiently frequent (N  15) we calcu-
lated the risk of HAM/TSP associated with that allele. We then calculated the risk of HAM/TSP asso-
ciated with alleles with similar TCR binding, similar inhibitory KIR binding, similar activating KIR
binding, similar LILRB1 binding and similar LILRB2 binding. Alleles which were underpowered (<15
alleles with greater than 50% similarity) were discarded. The results were striking (Figure 2). Across
all alleles there was a very strong positive correlation between the protection conferred by an allele
and the protection conferred by other alleles with similar TCR binding (Rs = + 0.76 p=510 6,
Spearman Correlation two tailed). 29 alleles were considered, in every case if the index was protec-
tive then alleles with similar TCR binding were also protective and if the index allele was detrimental
then alleles with similar TCR binding were also detrimental (p=410 9, Binomial test). No such asso-
ciation was seen for any of the other measures of similarity (Figure 2). However, if we restricted the
NK analysis to KIR binding alleles (ie. alleles with a C1, C2 or Bw4 motif) than a weak association was
also seen for iKIR (Rs = 0.6, p=0.07, Spearman Correlation two tailed) but not for aKIR. The protec-
tion/susceptibility associated with an allele’s nearest neighbours in CD8+ T cell recognition space
was a significant determinant of protection/susceptibility (p=0.0006) even when all other metrics
were included in the model.
We conclude that, in HTLV-1 infection, the peptide:TCR binding properties of an allele is a signifi-
cant determinant of the risk of disease associated with that allele; this is true not only for the
extreme case alleles which are associated with significant protection or susceptibility but also for the
intermediate ‘average’ alleles without significant associations.
HIV-1 infection: what determines the susceptibility associated with HLA
class I alleles?
We studied a well-characterised cohort of HIV-1 seroconverters from sub-Saharan Africa who were
identified when seronegative and followed under Protocol C of IAVI (International AIDS Vaccine Ini-
tiative, 2020; Kamali et al., 2015). Two allele groups were significantly associated with clinical out-
come in this cohort, consistent with findings in several other cohorts (Carrington et al., 1999;
Gao et al., 2001). HLA-B*35Px was associated with an increased viral load set point but did not
have a significant impact on progression. HLA-B*57 was associated with a low early viral load set
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Figure 2. Correlation between the risk of HAM/TSP associated with an allele and the risk associated with similar alleles. The risk of HAM/TSP
associated with an HLA class I allele (“Coefficient of Index Allele, x axis) was compared with the coefficient of HLA class I alleles with (A) similar TCR
binding, (B) similar iKIR binding, (C) similar activating KIR binding, (D) similar LILRB1 binding and (E) similar LILRB2 binding. All alleles in the cohort of a
sufficient frequency (N > 15) and with sufficient near alleles (N > 15 with 50% or more similarity) were considered. The Spearman correlation coefficient
Figure 2 continued on next page
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point and slow progression to low CD4 count. We first focussed on B*35Px and identified which
HLA alleles at the 4 digit level were driving the detrimental association. The detrimental effect was
entirely due to B*53:01 which was significantly associated with an increased early viral load set point,
all other B*35Px alleles were infrequent in this cohort; (Appendix 3—table 2).
HLA-B*53:01 is unusual in that its nearest allele out of all the 151 alleles in the cohort, in terms of
both TCR and KIR recognition was distant (only 46% similarity). We were therefore unable to per-
form the similarity analysis for TCR and KIR binding as there were no similar alleles. In contrast, we
were powered to study LILRB1 and LILRB2 as there were a large number of similar alleles by both
these metrics. However, alleles similar to B*53:01 in terms of LILRB1 and LILRB2 binding behaved
very differently in terms of their impact on clinical outcome: near alleles had no significant impact
either on early viral load set point nor on time to low CD4+ cell count; moreover, if anything, near
alleles tended to be slightly protective rather than detrimental (Table 2). We conclude that the detri-
mental effects of B*53:01 are independent of its LILRB binding properties but that we were not pow-
ered to study whether TCR or KIR binding effects were determinants of susceptibility.
HIV-1 infection: why are HLA-B*57 alleles protective?
Moving on to the protective B*57 allele group, we found that both B*57:02 and B*57:03 were signif-
icantly associated with a reduced early viral set point (Appendix 3—table 2). We also studied alleles
similar to B*57:01 since, although B*57:01 is very infrequent in this African cohort (N = 1 carrier), it is
well described to be protective in other cohorts and whilst there was no power to study B*57:01
directly in this cohort there was power to study near alleles by all five metrics. We found a clear pic-
ture that alleles with similar aKIR binding to B*57:01, B*57:02 and B*57:03 were significantly protec-
tive (Table 2). There was also a trend for alleles with similar TCR binding and similar LILRB2 binding
to also be protective when these metrics were considered in isolation. But when they were consid-
ered in a multivariate analysis with aKIR.FS only aKIR.FS retained significance. We conclude that the
main reason for the protective effect of HLA-B*57 in this cohort is attributable to its activating KIR
binding properties.
B*57:01, B*57:02 and B*57:03 all contain the Bw4-80I KIR binding motif and are thought to bind
KIR3DS1. So, the aKIR.FS for the B*57 alleles will be 0 for individuals who are KIR3DS1— or who do
not have an allele with a Bw4-80I motif and between 0 and 1 (depending on the degree of similarity
of their alleles to B*57) for individuals who have the compound genotype KIR3DS1:Bw4-80I (i.e. pos-
session of KIR3DS1 together with an HLA allele containing the Bw4-80I binding motif). So our finding
that HLA-B*57 is protective because of its aKIR binding properties is consistent with the report, in an
independent cohort, that KIR3DS1:Bw4-80I is protective (Martin et al., 2007). Interestingly, we
found that aKIR.FS was more protective (Coeff =  0.41 p=0.006 **) than KIR3DS1:Bw4-80I
(Coeff =  0.22 p=0.04 *). And, in a model including both terms, aKIR.FS remained protective
(Coeff =  0.52 p=0.07 .) whilst the compound genotype KIR3DS1:Bw4-80I loses significance and
becomes, if anything, detrimental (Coeff = +0.09, p=0.6). This indicates that though aKIR.FS and
KIR3DS1:Bw4-80I are related, they are capturing slightly different features and that aKIR.FS is a
stronger determinant of protection. To investigate the difference between aKIR.FS and KIR3DS1:
Bw4-80I we plotted the two variables against each other for each individual in the cohort
(Figure 3A). This identified three distinct groups of people that all had identical KIR3DS1:Bw4-80I
status (all being KIR3DS1+ HLA-Bw4-80I+) but with high (0.6–1), medium (0.4–0.6) or low (0–0.4)
Figure 2 continued
(Rs) and corresponding P value are reported in the title bar for each plot. There is a very striking positive correlation for TCR binding, i.e. the risk of
HAM/TSP associated with an allele is strongly correlated with the risk associated with other alleles that share similar TCR binding properties. No such
correlation was observed for any of the other metrics.
The online version of this article includes the following source data for figure 2:
Source data 1. Data underlying Figure 2A.
Source data 2. Data underlying Figure 2B.
Source data 3. Data underlying Figure 2C.
Source data 4. Data underlying Figure 2D.
Source data 5. Data underlying Figure 2E.
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Table 2. Interactions underlying HLA class I disease associations in HIV-1 infection.
Four HLA class I alleles have been associated with early viral load set point in HIV-1 infection (model 1, index only). For each HLA allele
we sought to determine the underlying mechanism by performing five multivariate linear regressions (model 2–6), one for each of the
distance metrics. The coefficient (Coeff) and P value for the index allele and the similarity metric are recorded below. A Coeff >0 indi-
cates an increase in viral load i.e. a detrimental effect (D), a Coeff <0 indicates a protective effect (P). In all cases gender was included
as an additional covariate in the model. A slash (/) indicates that there were an insufficient number of alleles to perform the analysis.
For B53:01 there were not enough similar alleles to perform the TCR or KIR analysis. Alleles with similar LILRB1 and LILRB2 binding to
B53:01 were not similarly detrimental. For the protective B57 alleles, we found a clear picture that alleles with similar aKIR binding to
B*57:01, B*57:02 and B*57:03 were significantly protective (model 4, ‘aKIR.FS’ row, shaded). There was also a trend for alleles with simi-
lar TCR binding and similar LILRB2 binding to be protective (model 2 TCR.FS row and model 6 LILRB2.S row). Significance codes:
p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P values are two tailed.
Index allele
Model COV. B*53:01 B*57:01 B*57:02 B*57:03
1.
Index only
index Coeff +0.23
D
/  0.63
P
 0.46
P
P val 0.02
*
/ 0.005
**
0.002
**
2.
Index+TCR.FS
Index Coeff / /  0.65  0.48
P val / / 0.003
**
0.001
**
TCR.FS Coeff /  0.24
P
 0.33
P
 0.24
P
P val / 0.069

0.082

0.15
3.
Index+iKIR.FS
Index Coeff / /  0.64  0.47
P val / / 0.004
**
0.002
**
iKIR.FS Coeff /  0.12
P
 0.11
P
 0.08
P
P val / 0.19 0.32 0.47
4.
Index+aKIR.FS
Index Coeff / /  0.62  0.45
P val / / 0.005
**
0.002
**
aKIR.FS Coeff /  0.41
P
 0.43
P
 0.39
P
P val / 0.006
**
0.017
*
0.025
*
5.
Index+LILRB1.S
Index Coeff +0.21 /  0.67  0.49
P val 0.045
*
/ 0.003
**
0.001
**
LILRB1.S Coeff  0.11
P
 0.25
P
 0.59
P
 0.5
P
P val 0.65 0.27 0.22 0.27
6.
Index+LILRB2.S
Index Coeff +0.22 /  0.67  0.5
P val 0.03
*
/ 0.003
**
0.0007
***
LILRB2.S Coeff  0.06
P
 0.40
P
 0.56
P
 0.7
P
P val 0.84 0.08

0.08

0.08

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Figure 3. aKIR. FS reveals subtleties within the KIR3DS1:Bw4-80I grouping. When considering alleles with similar activating KIR binding properties to
HLA-B*57 we found that the fraction shared (aKIR.FS) was more informative than the traditional KIR3DS1:Bw4-80I compound genotype grouping. (A) On
plotting individuals’ KIR3DS1:Bw4-80I content against their aKIR fraction shared it can be seen that whilst KIR3DS1:Bw4-80I is a simple binary 1 or 0
(people either have the compound genotype or they do not), aKIR.FS has more subtlety and people with KIR3DS1 and Bw4-80I can be segregated into
three distinct groups (labelled group I, group II and group III in panel A). These three groupings have different impacts on viral load (i.e. different
coefficients in the multivariate regression; B, left hand plot) and only group I is actually significantly protective (Coeff =  0.4 p=0.007 **) although all
three groupings have identical KIR3DS1:Bw4-80I status. Group I is larger (N = 47 individuals) than group II (N = 19) or group III (N = 20). To check that
lack of significance in group II and group III was not simply due to cohort size we pooled group II and group III (B) right hand plot), group II and III were
still not significantly protective. Furthermore, when we downsampled the people in group I so that there were 39 people (i.e. exactly the same size as
group II+group III) and calculated the impact on log[viral load] there was never an instance in 5000 runs when the estimated protective effect (decrease
in log viral load) was as small as that seen in group II+III. This is illustrated in (C). The grey histogram is the distribution of coefficients seen upon
repeated downsampling of group I and the vertical red line is the coefficient associated with group II+III. It can be seen that in 5000 runs the protective
effect in the group I individuals far exceeds that in group II+III individuals despite (artificially) matched cohort size. Note in panel A jitter (a random
number between 0 and 0.2) has been added to the KIR3DS1:Bw4-80I variable on the x axis since this number only takes value 0 or 1, plotting without
jitter simply overlays the datapoints and information about the number of points in the clusters is obscured.
The online version of this article includes the following source data for figure 3:
Source data 1. Data underlying Figure 3A.
Source data 2. Data underlying Figure 3B.
Source data 3. Data underlying Figure 3C.
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aKIR.FS. Despite having the same KIR3DS1:Bw4-80I status these groupings are associated with very
different effects on viral load (Figure 3B, Appendix 3—table 4). In particular people with KIR3DS1
and the group I alleles (aKIR.FS >0.6) are strongly protected; an effect that is entirely dependent on
the presence of KIR3DS1 (group I allele with KIR3DS1 Coeff =  0.4 p=0.007 **; group I allele with-
out KIR3DS1 Coeff =  0.05 p=0.5). Whereas KIR3DS1 with the group II or group III alleles offers no
protection. Pooling the group II and group III individuals (to increase the numbers) did not change
the finding that group I but not group II+III is associated with a significantly reduced early viral load
set point (Figure 3B). Downsampling showed that this difference could not be explained simply by
group size (Figure 3C). This finding supports the utility of the fraction shared approach. Here we
find that aKIR.FS confirms what is known about KIR3DS1:Bw4-80I but extends it beyond a simple
binary descriptor adding extra information that is clearly biologically relevant.
Finally, since there was a trend for alleles with similar TCR binding and similar LILRB2 binding to
B*57 to also be protective, we investigated whether there was any evidence for a protective effect
of B*57 independent of KIR3DS1. To this end we excluded everyone with KIR3DS1 from the cohort.
HLA-B*57:02 and B*57:03 both remained significantly protective amongst KIR3DS1— individuals
(Coeff =  0.58 p=0.027 *, Coeff =  0.39 p=0.019 *) indicating that not all of the B*57:02 and
B*57:03 protective effect is attributable to their role as KIR3DS1 ligands. Amongst KIR3DS1— indi-
viduals the best model to explain the residual protective effect of B*57:02 and B*57:03 was provided
by their TCR binding, i.e. alleles with similar TCR binding were significantly protective (Appendix 3—
table 5).
We conclude that HLA-B*57 alleles are protective for two reasons: firstly (and most importantly)
because of their activating KIR binding properties; secondly, their TCR binding properties.
HIV-1 infection: what determines the impact on viral load set point
across all alleles?
As for HTLV-1 infection, we next investigated the interactions responsible for the early viral load
associations of average alleles. As before, we first investigated whether the viral load associations of
average alleles was meaningful. We found that rank order of intermediate alleles was highly robust
and significantly more informative than random (p<10 16 two sample Kolmogorov-Smirnov Test
two-tailed) Appendix 2 Supplementary Results ‘Are average HLA class I associations robust’, Appen-
dix 4—figure 2).
Unlike HTLV-1 infection, and more in line with expectation, the picture was mixed with no single
interaction able to explain all HLA associations (Appendix 4—figure 3). The only significant correla-
tion was between the protection offered by an allele and the protection offered by alleles with simi-
lar LILRB2 binding. However, the correlation was weak (Rs = 0.29 p=0.048, Spearman two-tailed)
and there were plenty of alleles which did not conform to the pattern (e.g. A*2902 is detrimental
but alleles with similar LILRB2 binding are protective).
We conclude that, in HIV-1 infection, different interactions are responsible for the protection con-
ferred by different HLA alleles. For the well-described protective effect of the B*57 alleles the domi-
nant effect was explained by binding to activating KIR with a weaker effect attributable to TCR
binding (revealed once individuals with KIR3DS1 were removed from the cohort). It is worth noting
that in our cohort, unlike in white US cohorts, KIR3DL1:Bw4 was not associated with protection.
HCV infection: what determines the protective effect of HLA-B*57?
We studied a case-control cohort of 782 HCV-seropositive individuals. 257 subjects had spontane-
ously cleared the virus, and 525 subjects were chronically infected. A number of published studies
have repeatedly found that the HLA-B*57 alleles are associated with increased odds of spontaneous
clearance and reduced viral load amongst those chronically infected (Kuniholm et al., 2013;
Kuniholm et al., 2010; Thio et al., 2002). Other alleles (including A*11:01, A*23:01, C*01:02,
C*04:01) have also been associated with outcome in some studies but are not consistently replicated
(and in particular these effects have not been reproduced in the studies with the largest cohorts) so
we focus solely on the B*57 alleles. In the cohort we studied, the B*57 protective effect appeared to
be attributable to B*57:02 (with B*57:03 and B*57:05 showing similar effects but were not statisti-
cally significant due to low carrier numbers); the more frequent B*57:01 allele did not appear to be
protective (Appendix 3—table 6).
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Unlike in HIV-1 infection, where the B*57 protective effect is mainly due to aKIR interactions, in
HCV infection there was no evidence that the aKIR-binding properties of the B*57 alleles contributed
to their protection (model 4 in Table 3 all the P values for aKIR.FS are very high, all the Coefficients
are close to zero) despite adequate power. Instead the protective effect was explained by TCR.FS
(model 2) indicating that CD8+ T cells are most likely responsible for the protective effect of HLA-
B*57 in HCV infection. The models used contained a number of nominal covariates (4), it has been
shown that under some circumstances, inclusion of such covariates in logistic regression can reduce
power (Pirinen et al., 2012). We therefore repeated the analysis of models 1–6 omitting the covari-
ates. This strengthened the finding that the protective effect was attributable to TCR.FS in every
case leading to an increase in the size of the coefficient and a decrease in the P value (Coeff = 1.09,
p=0.03 *, Coeff = 1.00 p=0.04 *, Coeff = 1.25 p=0.02* for TCR.FS with B*57:02, B*57:03 and
B*57:05 respectively). In contrast aKIR.FS never became significant.
Looking across all alleles, there was again substantial evidence that the rank order of protection
conferred by average alleles was robust (p<10 16 two-sample Kolmogorov-Smirnov Test, 93.8% of
runs significant, Appendix 2 Supplementary Results ‘Are average HLA class I associations robust’,
Appendix 4—figure 2). As for HIV-1 infection, the picture was mixed with no single interaction able
to explain all HLA associations (Appendix 4—figure 4). The strongest positive correlation was seen
for alleles with similar TCR binding (Rs = 0.21 p=0.09, Spearman two-tailed) but the correlation is
weak and not significant indicating that although the protection conferred by some alleles is attribut-
able to TCR binding there are many alleles where the protection is better explained by another
factor.
Crohn’s disease: can we understand the protective effect of the
ancestral AH8.1 haplotype?
The ancestral haplotype AH8.1 (also known as MHC 8.1) is a multigene haplotype consisting of HLA-
A*01:01 -B*08:01- C*07:01 -DRB1*03:01 -DQA1*05:01 -DQB1*02:01. Genes from AH8.1 or the com-
plete haplotype have been associated with risk or severity of disease in a number of inflammatory
and autoimmune conditions including autoimmune hepatitis, myasthenia gravis, systemic lupus
erythematosus, type 1 diabetes, a range of myositis phenotypes and Crohn’s disease (Lee et al.,
2017; Price et al., 1999; Manabe et al., 1993; Miller et al., 2015; Gorodezky et al., 2006). We
investigated the association between good prognosis in Crohn’s disease and the HLA class I alleles
of the AH8.1 haplotype. In a cohort of 2650 Crohn’s disease cases, HLA-B*08:01 and HLA-C*07:01
(which are in tight linkage disequilibrium with each other and with the class II genes of the haplo-
type) but not HLA-A*01:01 were significantly associated with good prognosis (Appendix 3—table
7).
Strikingly, despite good power in every case, we did not find that alleles with similar TCR binding,
similar iKIR binding, similar aKIR binding or similar LILRB1 and LILRB2 binding to either B*08:01 or
C*07:01 were associated with good prognosis (Table 4). The results were very clear, in every case
the P values were very high and in some cases the direction of association was if, anything, reversed
(nearby alleles were detrimental). This suggests that the protection marked by B*08:01 and C*07:01
is either attributable to other genes in this extended haplotype or that B*08:01 and C*07:01 confer
protection by a mechanism other than immune receptor binding (Elahi et al., 2011; Candore et al.,
1995).
Discussion
We have developed an approach, based on biologically-plausible similarity metrics, to help identify
the immune interactions responsible for the protection or susceptibility associated with a given HLA
class I allele. First we applied this approach to investigate HLA disease associations in 3 viral infec-
tions. We studied a total of 11 HLA alleles from 6 allele groups. In every case, with the exception of
B*53:01 in HIV-1 infection (where we had insufficient power to study TCR, iKIR and aKIR) we were
able to successfully identify the most likely cause of the protective or detrimental effect. In HTLV-1
infection, the pattern was remarkably skewed. All 4 HLA disease associations were best explained by
TCR binding. This pattern actually extended to all HLA alleles, with a very strong correlation
between the protection conferred by an allele and the protection conferred by alleles with similar
TCR binding. This is a wholly unexpected result that implies that, in HTLV-1 infection, the most
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Table 3. Interactions underlying HLA class I disease associations in HCV infection HLA-B*57 is associated with increased odds of
spontaneous clearance of HCV.
In this cohort the protective effect is attributable to B*57:02 with B*57:03 and B*57:05 apparently following the same trend (though
due to low numbers it is impossible to be certain). For each B*57 allele of interest we sought to determine the underlying mechanism
by performing five multivariate linear regressions (model 2–6), one for each of the distance metrics. The coefficient (Coeff) and P value
for the index allele and the similarity metric are recorded below. HBV seropositivity, mode of infection, SNP rs1297986 and subcohort
were included as additional covariates in all models. A coefficient >0 indicates a protective allele (increased odds of spontaneous
clearance, P). Unlike the B*57 protective effect in HIV-1 infection, in HCV infection there appeared to be no contribution from activat-
ing KIR i.e. HLA with similar aKIR binding to B*57 were never significant protective despite sufficient power (model 4). The protective
effect here appears to be entirely attributable to CD8+ T cells (model 2, shaded). In all cases the protective effect of alleles with similar
TCR binding is actually more significant than the protective effect of the B*57 alleles themselves (model 1, index only). Significance
codes: p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P values are two tailed.
Index allele
Model COV. B*57:02 B*57:03 B*57:05
1.
Index only
index Coeff 2.02
P
0.57
P
15.5
P
P val 0.08

0.16 0.99
2.
Index+TCR.FS
Index Coeff 2.10 0.67 15.9
P val 0.07

0.10

0.99
TCR.FS Coeff 1.04
P
0.89
P
1.19
P
P val 0.05
*
0.09

0.04
*
3.
Index+iKIR.FS
Index Coeff 2.00 0.64 15.62
P val 0.08

0.12 0.99
iKIR.FS Coeff 0.35
P
0.40
P
0.50
P
P val 0.29 0.24 0.17
4.
Index+aKIR.FS
Index Coeff 2.06 0.58 15.49
P val 0.07

0.15 0.99
aKIR.FS Coeff 0.66
P
0.29
P
0.54
P
P val 0.15 0.56 0.30
5.
Index+LILRB1.S
Index Coeff 2.00 0.58 15.48
P val 0.09

0.16 0.99
LILRB1.S Coeff  0.15
D
0.15
P
 0.37
D
P val 0.90 0.91 0.77
6.
Index+LILRB2.S
Index Coeff 2.02 0.52 15.53
P val 0.08

0.20 0.99
LILRB2.S Coeff  0.02
D
 0.81
D
 0.02
D
P val 0.98 0.40 0.98
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Table 4. Interactions underlying HLA class I disease associations in Crohn’s disease cases.
AH8.1 is associated with increased odds of good prognosis amongst Crohn’s disease cases. In our cohort two classical HLA class I
alleles from this haplotype, B*08:01 and C*07:01 are associated with good prognosis (Appendix 3—table 7). For both B*08:01 and
C*07:01 we sought to determine the underlying mechanism by performing 5 multivariate linear regressions (model 2–6), one for each
of the distance metrics. The coefficient (Coeff) and P value for the index allele and the similarity metric are recorded below. Gender
was included as an additional covariate in all models. A coefficient <0 indicates a protective effect (P, decreased odds of poor progno-
sis), a coefficient >0 indicates a detrimental effect (D, increased odds of poor prognosis). Despite good power, similar alleles by all 5
metrics were never significantly protective (indeed in some cases tended towards being detrimental e.g. similar alleles by TCR or
LILRB1 binding). Inclusion of 3 non-MHC SNPs which were significant in a GWAS as covariates did not alter these conclusions. Signifi-
cance codes: p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P values are two tailed.
Index allele
Model COV. B*08:01 C*07:01
1.
Index only
index Coeff  0.50
P
 0.34
P
P val 3.56  10 7
****
0.0003
***
2.
Index+TCR.FS
Index Coeff  0.49  0.34
P val 9.96  10 7
****
0.0008
***
TCR.FS Coeff 0.65
D
0.041
D
P val 0.20 0.84
3.
Index+iKIR.FS
Index Coeff  0.50  0.34
P val 3.75  10 7
****
0.0007
***
iKIR.FS Coeff  0.08
P
0.02
D
P val 0.89 0.86
4.
Index+aKIR.FS
Index Coeff  0.50  0.34
P val 3.56  10 7
****
0.0003
***
aKIR.FS Coeff 0 0.001
D
P val 1 0.99
5.
Index+LILRB1.S
Index Coeff  0.50  0.28
P val 1.46  10 6
****
0.007
**
LILRB1.S Coeff  0.001
P
0.28
D
P val 1 0.09
.
6.
Index+LILRB2.S
Index Coeff  0.50  0.28
P val 2.28  10 6
****
0.007
**
LILRB2.S Coeff 0.007
P
0.28
P
P val 0.98 0.11
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important immune response in determining protection via all HLA alleles is overwhelmingly the
CD8+ T cell response. In HIV-1 infection, the picture was more balanced. The protective effect of
B*57:01, B*57:02 and B*57:03 was mainly due to aKIR with evidence for a weaker effect of TCR bind-
ing. Across all alleles no single interaction was responsible for the degree of HLA-mediated protec-
tion conferred. In HCV infection the B*57 alleles were also protective, but unexpectedly for a
different reason to in HIV-1. In contrast to HIV-1 infection, there was no evidence that protection
was attributable to aKIR instead TCR binding appeared to be the main determinant. We then
applied the method to investigate the association between the classical HLA class I alleles of the
AH8.1 haplotype and good prognosis amongst cases of Crohn’s disease. The resulting picture was
very clear: none of the immune interactions investigated explained the protective effect. We con-
clude that either HLA-B*08:01 and C*07:01 mark a protective allele but are themselves not protec-
tive or that they protect via a mechanism independent of their receptor binding. A number of
studies have reported that the AH8.1 haplotype is associated with impaired immune activation, per-
haps due to a defect in the TCR signal transduction pathway (Candore et al., 1995; Lio et al., 1995;
Egea et al., 1991) in agreement with our conclusion that the protection associated with HLA-
B*08:01 and C*07:01 is not attributable to their receptor binding.
It is interesting to note that in HIV-1 infection all the B*57 alleles with high carrier frequency
(B*57:01, B*57:02, B*57:03) are associated with protection both in the cohort we study and in the
work of others (Carrington and O’Brien, 2003; Kiepiela et al., 2004; Costello et al., 1999;
Fellay et al., 2007). However, in HCV infection, B*57:02 and B*57:03 are protective, but the evi-
dence for B*57:01-mediated protection is less clear. B*57:01 is not significantly protective in the
cohort we study despite a large number of carriers and this has also been reported by others, for
example, Kuniholm et al. found both B*57:01 and B*57:03 were protective in a univariate analysis
but in a multivariate analysis B*57:01 lost significance (presumably due to linkage with other HLA
alleles) whilst B*57:03 retained significance (Kuniholm et al., 2013). Our metrics provide an explana-
tion for this divergent behaviour. The fraction shared metrics all depend upon the proteome of inter-
est. For the HIV-1 proteome, all the B*57 alleles are very similar (e.g. when the index is B*57:02 the
TCR.FS with B*57:01 is 0.74 and only 2 alleles –B*58:02 and B*57:03- are more similar). In contrast
for HCV, whilst B*57:02 and B*57:03 are similar, B*57:01 is more distant (e.g. when the index is
B*57:02 the TCR.FS with B*57:01 drops to 0.58 and 10 alleles are more similar to B*57:02 than
B*57:01). This provides a plausible explanation for why B*57:01 confers a similar degree of protec-
tion to B*57:02 and B*57:03 in the context of HIV-1 infection but appears to have less similarity in
the context of HCV infection. Another interesting observation was that, for all three viral infections,
the rank order of ‘average’ alleles was robust, that is, they could be robustly classified as protective
or detrimental.
Although there are a large number of reported HLA class I associations, it is not known which
immune interactions are responsible for any of these associations so there does not exist a ‘gold
standard’ test data set with which we can formally validate our approach. However, a number of
observations suggest that our approach is identifying biologically meaningful features. Firstly, the
TCR.FS metric finds that alleles within the same supertype are more similar (have a higher TCR.FS)
than alleles between supertypes (p=310 7). Secondly, for HTLV-1 infection we find a very strong
positive correlation between the risk of HAM/TSP associated with an allele and the risk of HAM/TSP
associated with similar alleles (by the TCR.FS metric). Such a strong correlation is unlikely to be gen-
erated by random. Thirdly, in HIV-1 infection we found that similarity in terms of activating KIR bind-
ing (aKIR.FS) revealed clinically relevant subtleties lost within the traditional KIR3DS1:Bw4-80I
protective group, essentially splitting this group into 3 groups with decreasing levels of protection;
again it is difficult to see how such a result could be generated other than by a method that was
reflecting biological reality.
We stress that this method should not be used in isolation as the sole method for determining
the mechanism underlying an HLA association. Rather it provides a line of evidence to be used
alongside other lines of evidence to triangulate to the most likely answer. In common with classical
disease association approaches (which use HLA alleles as predictors), this method should be used
with care. Many of the problems arising in classical HLA disease association studies, such as linkage
disequilibrium, unmeasured confounding variables or population stratification are less of a problem
with these metrics. This is because many alleles will be similar and contribute to the similarity metric
and it is unlikely that all similar alleles will all be in linkage disequilibrium with the same
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polymorphism or all correlated with the same confounder. Nevertheless linkage disequilibrium and
other correlations can and will distort the results and should be investigated. In short, the method
should not be used blindly, it should be used with care by someone with knowledge both of the bio-
logical problem and the structure of the dataset. Another limitation of this approach is the relatively
simple definition of the KIR binding groups which does not take into account the KIR allele or varia-
tions in KIR-HLA binding that break the C1/C2 and Bw4/Bw6 rules. Nevertheless, these simplistic
groupings have proved very powerful in other studies (Martin et al., 2007; Martin et al., 2002;
Pelak et al., 2011; Vince et al., 2014; Khakoo et al., 2004; Ahlenstiel et al., 2008; Nakimuli et al.,
2015), indicating that, to a first approximation, they are informative.
We do not study all known receptor-HLA interactions; instead we focus on receptor-ligand pairs
which are polymorphic and well-characterised. Specifically we investigate TCR-HLA:peptide, inhibi-
tory KIR-HLA:peptide, activating KIR-HLA:peptide, LILRB1-HLA and LILRB2-HLA. Inclusion of other
receptors-ligand interactions would follow the same approach but requires more data and better
characterisation of the receptors. In particular we did not investigate the CD94:NKG2A-HLA interac-
tion since, with current knowledge, we could only split alleles in a binary fashion into binders or non-
binders which would provide no power in subsequent analysis. The strength of binding is known to
be more subtle than this and to depend on the peptide interaction with both CD94 and NKG2A
(Petrie et al., 2008) but there is no comprehensive data to allow us to characterise this binding. We
do not study atypical effects of the HLA molecules (Elahi et al., 2011). Monomorphic receptor-
ligand pairs are not studied as these cannot explain polymorphic HLA associations.
In addition to identifying immune interactions underlying HLA class I disease associations this
approach could also be used alongside classical GWAS or candidate gene approaches as a tool for
investigating identified HLA associations. Lack of association between ‘near’ alleles and outcome
may indicated that the identified allele is a passenger marking the causal variant or a false positive.
Our approach differs from another important attempt to move from HLA associations to under-
standing function by Raychaudhuri et al. (2012). Raychaudrhuri et al extended the usual approach
of identifying alleles associated with disease traits and instead fine mapped associations down to
the level of amino acids. This high resolution approach identified 5 amino acids, all in the peptide
binding grove of HLA molecules, that were associated with seropositive rheumatoid arthritis. How-
ever, the authors assumed that variation in the CD8+ T cell response elicited must explain the
observed associations.
Studies of human disease are typically observational and correlative in nature. An exception to
this is genetic association studies which provide a rare and powerful opportunity to uncover causal
factors. Here we provide an approach for interrogating some of the most important genes for dis-
ease associations: the HLA class I genes. Ultimately, knowing the causal factors will lead to a better
understanding of the molecular pathways involved in disease pathogenesis and help to identify
potential therapeutic targets.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers Additional information
Software,
algorithm
Fraction shared This paper RRID:SCR_018250 https://github.
com/bjohnnyd/fs-tool
Software,
algorithm
NetMHCpan v4.0 https://services.
healthtech.dtu.
dk/service.php?
NetMHCpan-4.0
KIR and HLA genotyping
The HTLV-1, HIV-1 and HCV cohorts were previously KIR and HLA genotyped (Martin et al., 2002;
Jeffery et al., 1999; Thio et al., 2002; Khakoo et al., 2004; Seich Al Basatena et al., 2011;
Prentice et al., 2014; Boelen et al., 2018). For the Crohn’s cohort, subjects were genotyped by
imputation using the Immunochip (Illumina), GeneChip 500K array (Affymetrix) and the UK Axiom
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Biobank array (Affymetrix). HLA genotypes were imputed previously (Lee et al., 2017). For KIR
imputation we first estimated haplotypes for all individuals using SHAPEIT with parameters
states = 500, burn = 10, prune = 10, main = 50 and the HapMap b37 recombination map
(Delaneau et al., 2013). Then, for 984 individuals who were genotyped with the Immunochip, KIR
imputations was performed using 231 SNPs on chromosome 19. For 818 individuals typed using
GeneChip 500K Array, KIR imputation was based on 141 SNPs on chromosome 19. For 410 individu-
als genotyped with the UK Axiom Biobank array, KIR imputations was based on 145 SNPs on chro-
mosome 19. In all cases KIR imputation was performed using KIR*IMP (Vukcevic et al., 2015) with a
probability threshold of 0.5. The KIR haplotype imputation accuracy has been reported as 92% at a
0.5 probability threshold with a call rate greater than 90%. However, this accuracy is for copy-num-
ber imputation, we used KIR*IMP for imputing presence or absence alone, suggesting we would
achieve an accuracy greater than 92%.
Subjects
Ethics
This study was approved by the NHS Research Ethics Committee (13/WS/0064) and the Imperial Col-
lege Research Ethics Committee (ICREC_11_1_2). Informed consent was obtained at the study sites
from all individuals. The study was conducted according to the principles of the Declaration of
Helsinki.
IAVI (HIV-1 seroconverters)
IAVI is a prospective cohort of HIV-1 seroconverters who were identified when seronegative and fol-
lowed under Protocol C of IAVI (International AIDS Vaccine Initiative, 2020). All individuals were
treatment naı¨ve except for short-term prevention of mother-to-child transmission (these time points
were excluded). Two outcome metrics were studied: early viral load set point and time to low CD4
count. An individual’s ‘Early viral load set point’ is the mean log10 of viral load measurements taken
between 3–9 months post infection (84–252 dpi); ‘time to low CD4 count’, was defined as time from
estimated date of infection to CD4 count <350 cells/mm3. 44 individuals were missing early viral
load set point information but not time to low CD4; therefore for analysis where the outcome metric
was early viral load these 44 individuals were removed. All individuals who were missing HLA class I
or KIR genotype were excluded. The IAVI cohort consisted of N = 568 individuals with time to low
CD4 count information and N = 524 individuals with early viral load information. Cohort information
was obtained from the IAVI Protocol C investigators.
Kagoshima (HTLV-1 seropositives)
The HTLV-1 cohort (N = 392) consists of individuals of Japanese origin who resided in the Kagoshima
Prefecture, Japan. The cohort consists of 214 HAM/TSP patients and 178 asymptomatic carriers.
HAM/TSP was diagnosed according to World Health Organization criteria; asymptomatic controls
were recruited from the same geographical region. Two outcome measures were considered: dis-
ease status (HAM/TSP or asymptomatic carrier) and log10(proviral load). Cohort information was
obtained from the original investigators who established the cohort.
HCV (HCV seropositives)
The HCV cohort consists of four sub-cohorts of HCV-seropositive subjects: AIDS Link to Intravenous
Experience (ALIVE, N = 226) (Vlahov et al., 1991), Multicenter Hemophilia Cohort Study (MHCS,
N = 295) (Goedert et al., 1989), Hemophilia Growth and Development Study (HGDS, N = 100)
(Hilgartner et al., 1993) and a UK cohort (N = 161) (Khakoo et al., 2004; Seich Al Basatena et al.,
2011; Boelen et al., 2018). One outcome measure was considered: the odds of spontaneous viral
clearance. Cohort information was obtained from the lead investigators representing each of the
four cohorts following separate applications.
Crohn’s disease
The Crohn’s disease cohort consists of two, previously reported cohorts of Crohn’s disease cases (a
total of 788 poor-prognosis cases and 1424 good-prognosis cases) (Lee et al., 2017;
Wellcome Trust Case Control Consortium, 2007). One outcome measure was considered: the
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odds of poor prognosis. Cohort information was obtained from the original investigators, KIR gene
content was imputed as described above.
The similarity metrics
We constructed 5 similarity metrics to quantify how similar two alleles are in terms of their TCR bind-
ing, iKIR binding, aKIR binding, LILRB1 binding and LILRB2 binding.
T cell receptor fraction shared (TCR.FS)
The T cell receptor fraction shared (TCR.FS) is defined as the fraction of peptides bound by the
index allele whose motifs appear in the peptides bound by the query (non-index) allele. The motif
coordinates for TCR.FS are flexible, in the results reported here it is determined by the anchor posi-
tions 2 and the C terminus and the TCR contact residues position 3–6. Peptide length is also a vari-
able of the equation. In the results reported here a peptide length of 9 amino acids was used. In the
GitHub script (see key resources table above) peptide lengths of 8–11 amino acids are allowed.
TCR.FS ranges from 0 to 1. TCR.FS of 0 means that none of the motifs in the index-bound pepti-
des appear in the peptides bound by the non-index allele. If the TCR.FS is 1, then all the motifs in
the index-bound peptides appear in the peptides bound by the non-index allele.
Specifically, TCR.FS for an index allele Ai and a query allele Aj is defined as
TCR:FS ðAi;AjÞ ¼
jMi \Mjj
jMij
Where Mi is the list of TCR recognition motifs of index allele Ai, Mj is the list of TCR recognition
motifs of query allele Aj, Mi \Mj is the motifs in the list Mi that are also in the list Mj and |Mk| denotes
the number of motifs in the list Mk. Note the measure is asymmetric.
As a basic test of the TCR.FS metric we investigated the hypothesis that the TCR.FS would be
higher between alleles of the same supertype than between alleles of different supertypes. This
hypothesis was strongly supported (Supplementary Results, Appendix 4—figure 1).
Inhibitory KIR fraction shared (iKIR.FS) and activating KIR fraction
shared (aKIR.FS)
The inhibitory KIR fraction shared (iKIR.FS) is based on the inhibitory KIRs: KIR2DL1, KIR2DL2,
KIR2DL3, KIR3DL1 and KIR3DL2. The activating KIR fraction shared (aKIR.FS) is based on the activat-
ing KIRs: KIR2DS1, KIR2DS2, KIR2DS4 and KIR3DS1. If the index allele and query allele bind distinct
inhibitory KIR (based on positions 77 and 80) (Trowsdale, 2001; Moesta et al., 2008) their iKIR.FS is
set to zero; similarly if the index and query bind distinct activating KIRs, their aKIR.FS is set to 0. If
the index and query allele are both not known to interact with any inhibitory KIRs, their iKIR.FS is
assigned a value of 1 and the same being true for activating KIRs and aKIR.FS. Otherwise the iKIR.FS
and aKIR.FS is set to a value to reflect the number of shared KIR recognition peptide motifs similar
to the TCR.FS. KIR recognition motifs being defined by the KIR contact positions 7 and 8 and the
peptide anchor positions 2 and C. Specifically, iKIR.FS for an index allele Ai and a query allele Aj is
defined as
iKIR:FSðAi;AjÞ ¼
0 Ai and Aj bind different iKIR
0 Ai and Aj bind the same iKIR; individual is iKIR
 
1 neither Ai nor Aj bind any iKIR
Mi\Mj
Mij j
Ai and Aj bind the same iKIR; individual is iKIR
þ
8><
>:
Where Mi is the list of KIR recognition motifs of index allele Ai, Mj is the list of KIR recognition
motifs of query allele Aj, Mi \Mj is motifs in the list Mi that are in the list Mj and |Mk| denotes the
number of motifs in the list Mk. aKIR.FS is defined similarly.
LILRB1 and LILRB2 similarity scores (LILRB1.S, LILRB2.S)
The LILRB1 and LILRB2 similarity scores are based on the LILR-HLA binding data reported by Bashir-
ova et al. in their Supplementary Table S1 (Bashirova et al., 2014).
The LILRB1 similarity score (LILRB1.S) between an index allele Ai and a query allele Aj is defined
as:
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LILRB1:S Ai;Aj
  
¼ 1 
jB LILRB1;Aið Þ B LILRB1;Aj
  
j
max jB LILRB1;Akð Þ B LILRB1;Amð Þjf g
where B(LILRB1,Ai) is the binding score between LILRB1 and the HLA allele Ai reported
(Bashirova et al., 2014) and alleles Ak and Am are all HLA alleles whose LILRB1 binding score has
been measured (Bashirova et al., 2014). The denominator (which is the same for all allele pairs Ai,
Aj) normalises the score to the maximum difference in binding scores observed so that LILRB1.S is
on the same scale as the other metrics; i.e. 1 corresponds to maximum similarity and zero corre-
sponds to maximum disparity. The LILRB1 similarity scores are calculated on a locus by locus basis. If
the LILRB1 binding score for a particular HLA allele has not been measured by Bashirova et al.
(2014) then the similarity score was calculated by taking the mean of all similarity scores for alleles in
the same 2-digit group. The LILRB2 similarity scores are defined in an analogous way.
Worked examples of the similarity score calculations are provided in Appendix 1 Supplementary
Methods.
Prediction of peptide: HLA class I molecule binding
NetMHCpan version 4.0 was used to predict the peptides bound by a given HLA class I molecule.
The stand-alone software package was used to perform binding affinity predictions (-BA) for pepti-
des of length 8 to 11. A percentile rank of 2% was used as the threshold for bound peptides with
peptides below this rank being considered to be bound (Nielsen et al., 2007; Jurtz et al., 2017).
Proteomes
Whole proteomes were obtained from Uniprot, 2018. For HTLV-1, the subjects were from Kagosh-
ima and so the HTLV-1 subtype prevalent in Japan was used (Uniprot accession: J02029). For IAVI
(subjects from East and South Africa), Zambian HIV-C subtype was used (Uniprot accession:
AB254142). For HCV (subjects from US and UK) HCV subtype 1a was used (Uniprot Accession:
M62321). For Crohn’s Disease 100 random human proteins were used. For small proteomes (e.g.
the viral proteomes considered here which were all less than 5000 amino acids) then results differ
depending on the choice of proteome (e.g. alleles which are similar in terms of binding to HCV are
not necessarily similar in terms of binding to HIV-1) but once the proteome becomes large, then the
exact choice of proteome does not impact the results.
Application of the metrics to a cohort
Each individual in each cohort was allocated 5 measures representing the distance of the nearest
allele in their genotype to the index allele in TCR recognition space, iKIR recognition space etc (for
all 5 similarity metrics). That is, an individual heterozygote at all 3 loci (HLA-A, HLA-B, HLA-C) would
have 6 different TCR.FS values for a specific index allele; the maximum of these six TCR.FS values
(i.e. the nearest allele in their genotype) would be allocated to the individual. This methodology was
applied for all metrics.
Regression
Multivariate linear, logistic and Cox regression was used to quantify the impact of the index allele
and near alleles by the different similarity metrics on the outcome of interest. Potentially confound-
ing covariates were identified and included in the analysis (listed in Appendix 1 Supplementary
Methods). The analysis was of the form:
Outcome ~ Indexallele þ FSmetric þ covariates
And was repeated for each of the 5 metrics. Combinations of metric were also considered to
determine independence and relative sizes. In the scenario where the same index HLA allele is pro-
tective or detrimental via different mechanisms in different people, then this would be detectable as
two independently protective (or detrimental) FS metrics (i.e. that did not lose significance when
included in the regression together); as an example of this please see the results section”HIV-1 infec-
tion: why are HLA-B*57 alleles protective’ in which different mechanisms of protection are identified
in different people. All reported P values are two tailed. Calculations were performed using R v3.4.1
(R Development Core Team, 2014).
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Workflow app
An implementation of this method is available on Github at https://github.com/bjohnnyd/fs-
tool (Debebe et al., 2020; copy archived at https://github.com/elifesciences-publications/fs-tool).
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Appendix 1
Supplementary methods
Regression
Impact of index allele and near alleles on outcome was analysed by multivariate regression
using R v3.4.1 (R Development Core Team, 2014). Continuous variables (log HIV viral load)
were analysed by linear regression (using the function lm), dichotomous variables (HAM/TSP
and spontaneous clearance of HCV) by logistic regression (using the function glm) and survival
analysis by Cox regression (using the function coxph). All reported P values are two tailed.
Covariates
Covariates which were significant predictors of outcome were identified and included in the
analysis. The following covariates were included:
Infection Outcome Covariates
HIV-1 Early viral load set point gender
HIV-1 Time to CD4 count < 350 cells/mm3 age at infection, clinic site*
HTLV-1 HAM/TSP gender, age
HCV Spontaneous clearance hepatitis B virus seropositivity, mode of
infection, SNP rs1297986, subcohort
*HIV clinic site is essentially collinear with viral subtype but available for more subjects
Consider the case when we wish to investigate the immune interactions underlying the
protective effect of HLA-C*08:01 on the risk of HAM/TSP in the HTLV-1 infected cohort. In
the first instance the following six logistic regressions would be conducted:
1. index only Disease statusC*08:01 + age +gender
2. Index + TCR.FS Disease statusC*08:01 + TCR.FS + age +gender
3. Index + iKIR.FS Disease statusC*08:01 + iKIR.FS + age +gender
4. Index + aKIR.FS Disease statusC*08:01 + aKIR.FS + age +gender
5. Index + LILRB1.S Disease statusC*08:01 + LILRB1.S + age +gender
6. Index + LILRB2.S Disease statusC*08:01 + LILRB2.S + age +gender
If the situation arose where more than one of the similarity metrics was significant then at
the next stage both metrics would be included in a regression model (along with the index
and covariates) to test if they were acting independently and if not which was the driving
association.
Worked examples of the fraction shared calculations
Two worked examples are presented in Supplementary file 1.
Details of the similarity metric
In formulating the similarity metrics a number of decisions had to be made on their exact
details. Here we describe some of those details and explain the reasoning behind them.
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Duplicate peptides
It is possible that the same peptide will appear more than once in a proteome; either
because different proteins are read from the same reading frame (e.g. p8 and p12 in HTLV-1)
or simply because the length of the proteome and the finite number of peptides means that
eventually peptides will be repeated. We decided to retain duplicate peptides rather than
restricting the analysis to unique peptides. We reasoned that restriction to unique peptides
would ignore the possibility that mutation in repeated (overlapping) peptides may carry a
heavier fitness cost, that repeated peptides may be more exposed to presentation (e.g.
accessibility to proteases may vary for different proteins) and that repeated targeting of the
same peptide is part of an HLA molecule’s recognition profile.
Nearest single allele
When considering the proximity of an individual’s HLA to a given index HLA we could
consider either the single nearest HLA they possess (i.e. take the maximum fraction shared
across all alleles they code for) or try to account for all HLA alleles they possess (e.g. take the
average). We decided to consider the single nearest allele for comparability with a standard
presence/absence analysis (the identity of the other alleles is irrelevant provided the index is
present).
KIR alleles
KIRs are polymorphic and these polymorphisms can affect the strength of HLA binding. We
have not considered differences in KIR alleles for several reasons: firstly many cohorts are
only typed to the level of KIR gene presence/absence and so requirement for allelic
information would exclude many datasets, secondly we do not attempt to capture strength
of HLA binding (either to peptide or to KIR) since the relationship between strength of
binding and strength of signalling is unclear and thirdly the strength of KIR allele: HLA allele
binding has only been measured for a very limited number of pairs and typically without
considering the impact of peptide so it would not be possible to accurately include KIR allele
information.
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Appendix 2
Supplementary results
Analysis of TCR.FS within and between supertypes
An HLA class I supertype is a group of HLA class I alleles which have been identified to have
similar peptide binding properties (Sette and Sidney, 1999; Sidney et al., 2008). We
hypothesised that the TCR.FS metric would be higher between alleles within the same
supertype than between alleles belonging to different supertypes. To test this hypothesis, we
chose 15 alleles to represent each of the 10 supertypes as defined by Sidney et al.
(2008). that is a total of 150 alleles. For each pair of supertypes, we calculated the inter-
supertype TCR.FS by taking the median of the TCR.FS between each representative allele of
the first supertype and each representative allele of the second supertype (i.e. a median of a
total of 15  15 = 225 measurements yielding one number which represents the distance
between that pair of supertypes). Similarly, for the intra-supertype distance, we take the
median of the TCR.FS between each pair of representative alleles of the supertype (i.e. the
median of a total of 15  14 = 210 measurements). So, for each supertype there is 1
intrasupertype distance and 9 intersupertype distances (the distance to each of the 9 other
supertypes). The results are plotted in Appendix 4—figure 1. It can be seen that for every
supertype the intra-supertype TCR similarity (TCR.FS) is always larger than the inter-supertype
similarity (p=310 7) confirming our hypothesis.
Are ‘average’ HLA class I associations robust?
We investigated whether there was any meaning in the rank order of protection associated
with different ‘average’ alleles; that is alleles not significantly associated with protection or
susceptibility. For each of the cohorts (of size N) of interest we randomly picked two
subcohorts (of size N/2) and identified alleles that were present in both subcohorts at
sufficient frequency (N  15). We discarded ‘extreme’ alleles which are significantly associated
with outcome in the cohort (i.e. HTLV-1: A*02:06, A*02:07, C*08:01, B*54:01. HIV-1: B*53:01,
B*57:02, B*57:03. HCV: B*57:01) thus leaving only ‘average’ alleles. Then, for each of the
remaining alleles, in each subcohort we calculated the coefficient of that allele’s protective or
detrimental effect using multivariate regression. The covariates included were the covariates
already shown to be significant for that measure of outcome in that cohort (see Methods) plus
the significant protective/detrimental alleles as listed above. We then asked whether the
coefficients calculated in each subcohort were correlated using Pearson’s correlation
coefficient (i.e whether the protection associated with a given average allele in one subcohort
was correlated with the protection associated with the same allele in the other subcohort).
This process was repeated 500 times and the correlation coefficients and P values recorded.
The results are plotted in Appendix 4—figure 2, ‘observed’, green shading. For comparison
we also repeated the process but this time looking for a correlation between mismatched
alleles; these results are plotted as ‘random’, red shading in the same figure.
In all cases the observed correlation was highly significantly different from random
(p<10 16, comparing the red and green shaded areas in Appendix 4—figure 2). However,
although clearly distinct from random, the observed correlations were not always significant
(histogram of green observed P values, right hand column Appendix 4—figure 2, contains a
number of P values > 0.05). The percentage of runs with P values < 0.05 are as follows: HTLV-
1 disease 62.6%, HTLV-1 proviral load asymptomatic carriers 22%, HTLV-1 proviral load HAM/
TSP patients 30.6%, IAVI early viral load set point 98.6%, IAVI time to low CD4 count 99.0%,
HCV odds of spontaneous clearance 93.8%.
So, with the exception of the two HTLV-1 proviral load outcomes, we found that the rank
order of ‘average’ HLA class I molecules was robust, with the majority of runs yielding a
statistically significant correlation. This was particularly true for the alleles in HIV-1 and HCV
infection. Henceforth, we did not consider the impact of average alleles on HTLV-1 proviral
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load as the results were not robust (possibly because of low cohort size). For all other outcome
metrics in all other cohorts we consider the measured impact of ‘average’ alleles on outcome
to be meaningful.
In contrast, for the random data (i.e. mismatched alleles), the percentage of runs with P
values < 0.05 are as follows: HTLV-1 disease 6.0%, HTLV-1 proviral load asymptomatic carriers
5.5%, HTLV-1 proviral load HAM/TSP patients 4.8%, IAVI early viral load set point 6.2%, IAVI
time to low CD4 count 4.8%, HCV odds of spontaneous clearance 4.8%; that is close to 5% in
each case as expected.
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Appendix 3
Supplementary tables
Appendix 3—table 1. Which HLA subtype alleles are responsible for the allele group
associations in HTLV-1 infection? Risk of HAM/TSP was determined by logistic regression; we
report the coefficient [odds ratio of HAM/TSP = exp(Coeff)], P value and number of individuals in
the cohort with and without the HLA allele of interest. In all models, age and gender were
included as additional covariates. Significance codes: p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P
values are two tailed.
Risk of HAM/TSP N
Coeff P value HLA+ HLA-
A*02  0.85 0.0014
**
150 242
A*02:01  0.33 0.40 49 343
A*02:06  0.55 0.086

74 318
A*02:07  1.27 0.0079
**
30 362
C*08  0.70 0.064

56 336
C*08:01  0.52 0.19 50 342
B*54 0.96 0.0056
**
82 310
B*54:01 0.96 0.0056
**
82 310
Appendix 3—table 2. Which HLA subtype alleles are responsible for the allele group
associations in HIV-1 infection? Predictors of Log10(early viral load set point) were determined
by linear regression. Other significant covariates (gender) were included in the model. A
negative coefficient (Coeff) indicates a protective effect (decrease in log viral load associated
with possession of the allele); a positive coefficient indicates a detrimental effect. Predictors of
the rate of progression to CD4 cell count <350 cells/mm3 was determined by Cox regression;
hazard ratio = exp(Coeff). Other significant covariates (age at infection, and HIV-1 clinic site
which is essentially collinear with viral subtype but available for more subjects) were included in
the model. A hazard ratio (HR) less than 1 indicates a protective effect (reduced risk of
progression to low CD4 count associated with possession of the allele); a HR greater than 1
indicates a detrimental effect. N is the number of individuals with early viral load information
(numbers with time to low CD4 cell count are slightly higher, total cohort size=568).
Significance codes: p<0.001 ***; p<0.01 **; p<0.05 *; p<0.1. ; P values are two tailed.
Early viral load set point
Time to low CD4 cell
count N
Coeff P val HR P val HLA+ HLA-
B*57  0.51 0.00005
***
0.48 0.01
*
50 474
B*57:01 Insufficient numbers for analysis 1 523
B*57:02  0.63 0.005
**
0.40 0.07 15 509
B*57:03  0.46 0.002
**
0.50 0.04
*
36 488
Appendix 3—table 2 continued on next page
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Appendix 3—table 2 continued
Early viral load set point
Time to low CD4 cell
count N
Coeff P val HR P val HLA+ HLA-
B*35Px +0.23 0.02
*
1.0 1.0 98 426
B*35:02 Insufficient numbers for analysis 3 521
B*53:01 +0.23 0.02
*
+0.93 0.7 95 429
Appendix 3—table 3. Interactions underlying HLA class I associations with disease
progression in HIV-1 infection. We investigated the interactions underlying HLA class I alleles
which were significantly associated with disease progression in HIV-1 infection. HLA-B*53:01
was not included in this analysis as, in this cohort, it has no impact on progression to low CD4+
cell count (HR = 0.9, p=0.7).
Index allele
Model COV. B*57:01 B*57:02 B*57:03
1.
Index only
index HR / 0.40 0.50
P val / 0.07

0.04
*
2.
Index+TCR.FS
Index HR / 0.40 0.49
P val / 0.07 0.04
*
TCR.FS HR 0.79 0.79 0.92
P val 0.33 0.5 0.8
3.
Index+iKIR.FS
Index HR / 0.40 0.50
P val / 0.07

0.04
*
iKIR.FS HR 0.97 1.01
P val 0.87 0.97
4.
Index+aKIR.FS
Index HR / 0.41 0.51
P val / 0.08

0.05
*
aKIR.FS HR 0.60 0.61 0.61
P val 0.098

0.17 0.16
5.
Index+LILRB1.S
Index HR / 0.35 0.39
P val / 0.04
*
0.006
**
LILRB1.S HR 0.83 0.19 0.004
P val 0.67 0.06

0.0001
***
6.
Index+LILRB2.S
Index HR / 0.40 0.49
P val / 0.07

0.04
*
LILRB2.S HR 0.95 0.92 0.79
P val 0.90 0.90 0.76
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Appendix 3—table 4. Impact on log10 viral load associated with different aKIR.FS
groupings. Investigation of individuals with similar aKIR binding to HLA*B57:01 revealed three
distinct grouping (Figure 3A) which we named I, II and III. In a multivariate linear model to
predict log10(viral load) these three different groupings (treated as three levels of a factor) had
different coefficients, with only group I being significantly protective (top 3 rows of table
below). Pooling groups II and III to increase the number of individuals in this grouping did not
change the conclusion that only group I had a significant protective effect (bottom two rows of
table below). Comparisons are with respect to the baseline (KIR3DS1:Bw4-80I- individuals,
N = 438). In all cases gender was also included as a covariate in the model.
Coefficient P value N in group
Group I  0.38 0.007 ** 47
Group II  0.16 0.45 19
Group III +0.05 0.78 20
Group I  0.38 0.007 ** 47
Group II+III  0.04 0.76 39
Appendix 3—table 5. Interactions underlying HLA class I associations with early viral load
set point in HIV-1 infection in a KIR3DS1- cohort. We investigated the interactions
underlying HLA class I alleles which were significantly associated with early viral load set point
in the absence of KIR3DS1 in HIV-1 infection. For all three alleles the winning model was one in
which both TSC.FS and iKIR.FS were covariates (model 7) but in this case only TCR.FS (i.e.
alleles with similar TCR binding, shaded) were significantly protective, alleles with similar iKIR
binding actually tended to be detrimental (though not significantly) so they cannot explain the
protective effect of the B*57 alleles.
Index allele
Model COV. B*57:01 B*57:02 B*57:03
1.
Index only
index Coeff /  0.58  0.39
P val / 0.027
*
0.019
*
2.
Index+TCR.FS
Index Coeff /  0.59  0.43
P val / 0.023
*
0.011
*
TCR.FS Coeff  0.22  0.32  0.29
P val 0.13 0.12 0.11
3.
Index+iKIR.FS
Index Coeff /  0.59  0.40
P val / 0.025
*
0.017
*
iKIR.FS Coeff  0.09  0.088  0.05
P val 0.37 0.47 0.65
4.
Index+aKIR.FS
Index Coeff /  0.58  0.39
P val / 0.027
*
0.019
*
aKIR.FS Coeff / / /
P val / / /
Appendix 3—table 5 continued on next page
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Appendix 3—table 5 continued
Index allele
Model COV. B*57:01 B*57:02 B*57:03
5.
Index+LILRB1.S
Index Coeff /  0.68  0.42
P val / 0.01
*
0.013
*
LILRB1.S Coeff  0.46  1.22  0.51
P val 0.058

0.02
*
0.3
6.
Index+LILRB2.S
Index Coeff /  0.66  0.46
P val / 0.012
*
0.006
**
LILRB2.S Coeff  0.56  0.80  1.04
P val 0.023
*
0.02
*
0.02
*
7. Index+TCR.FS+iKIR.FS Index Coeff /  0.57  0.42
P val / 0.027
*
0.01
*
TCR.FS Coeff  0.86  0.62  0.81
P val 0.046
*
0.087

0.022
*
iKIR.FS Coeff 0.48 0.21 0.38
P val 0.12 0.32 0.086.
Appendix 3—table 6. Which HLA subtype alleles are responsible for the protective effects
of HLA-B*57 in HCV infection? Odds of spontaneous clearance of HCV was determined by
logistic regression; we report the coefficient (Coeff), P value and number of individuals in the
cohort with and without the HLA allele of interest. In all models, HBV seropositivity, mode of
infection, SNP rs1297986 and subcohort were included as additional covariates. A coefficient >0
indicates a protective allele (increased odds of spontaneous clearance). The odds ratio of
spontaneous clearance = exp(Coeff). Significance codes: p<0.001 ***; p<0.01 **; p<0.05 *;
p<0.1. ; P values are two tailed.
Odds of spontaneous
clearance N
Coeff P value HLA+ HLA-
B*57 0.62 0.01
*
84 698
B*57:01 0.41 0.20 49 733
B*57:02 2.02 0.08

5 777
B*57:03 0.57 0.16 29 753
B*57:05 15.53 0.99 1 781
Appendix 3—table 7. Which HLA class I alleles of the AH8.1 haplotype are associate with
reduced odds of poor prognosis? Odds of poor prognosis was determined by logistic
regression; we report the Coefficient (Coeff), Odds ratio (OR), P value and number of
individuals in the cohort with and without the HLA class I allele of interest. OR = exp(Coeff). An
OR <1 (or equivalently a Coeff <0) indicates a protective allele (odds of poor prognosis
reduced). To maximise power, only individuals missing information at loci of interest were
removed hence there is some variation in cohort size depending on the analysis. 1 3 SNPs
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included: rs5929166, rs147856773 and rs75764599. See Lee et al., 2017 for details. In all cases
gender was included as a covariate. Since inclusion of the 3 SNPs had little impact on the OR
but reduced power (due to a loss of individuals) we do not include the 3 SNPs as covariates in
subsequent analysis but we do check that results are robust to their inclusion.
Odds of poor prognosis N
HLA Coeff OR P value HLA+ HLA- Total
A*01:01  0.08 0.92 0.33 859 1643 2502
B*08:01  0.48 0.62 4.75  10 7
****
620 1837 2457
C*07:01  0.29 0.75 9.8  10 4
***
784 1866 2650
1 With inclusion of three non-MHC SNPs significant in GWAS as covariates
A*0101  0.05 0.95 0.55 813 1531 2344
B*08:01  0.43 0.65 1.57  10 5
****
584 1714 2298
C*07:01  0.24 0.78 8.3  10 3
**
740 1738 2478
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Appendix 4
Supplementary figures
Appendix 4—figure 1. TCR. FS Intra-Supertype and Inter-Supertype. (A) For each of the 10
supertypes (x axis) we calculated the similarity (median TCR.FS, y axis) to alleles within that
supertype (red triangles) and to alleles within all other 9 supertypes (green circles). It can be
seen that for every supertype the intra-supertype similarity is larger than all the inter-
supertype similarities for that supertype. (B) Pooling the intra-supertype similarities and
comparing them with pooled inter-supertype similarities we find that the intra-supertype
similarities are significantly higher (p=310 7, Wilcoxon two tailed test), horizontal lines
represent the medians of the two groups.
The online version of this article includes the following source data is available for figure 1:
Appendix 4—figure 1—source data 1. Data underlying Appendix 4—figure 1A.
Appendix 4—figure 1—source data 2. Data underlying Appendix 4—figure 1B.
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Appendix 4—figure 2. Is the rank order of ‘average’ HLA class I alleles robust? For each
cohort and each outcome measure (panels A-F) the cohort was split in half and the correlation
between the protection/susceptibility for the average alleles was calculated using Pearson’s
method; this process was repeated 500 times (resulting in 500 correlation coefficients and 500
P values). The distribution of the correlation coefficients (left hand plot in each panel) and the
corresponding P values (right hand plot in each panel) was calculated and plotted (green
shading). The distributions for randomly paired alleles were also calculated (red shading). In
every case the observed distributions were significantly different from random (p<10 16).
However, although distinct from random, the observed correlations were not always significant
(histogram of green observed P values, right hand plots, contains a number of P
values > 0.05). The percentage of runs with P values < 0.05 are as follows: HTLV-1 disease
62.6%, HTLV-1 proviral load asymptomatic carriers 22%, HTLV-1 proviral load HAM/TSP
patients 30.6%, IAVI early viral load set point 98.6%, IAVI time to low CD4 count 99.0%, HCV
odds of spontaneous clearance 93.8%.
The online version of this article includes the following source data is available for figure 2:
Appendix 4—figure 2—source data 1. Data underlying Appendix 4—figure 2A.
Appendix 4—figure 2—source data 2. Data underlying Appendix 4—figure 2A.
Appendix 4—figure 2—source data 3. Data underlying Appendix 4—figure 2B.
Appendix 4—figure 2—source data 4. Data underlying Appendix 4—figure 2B.
Appendix 4—figure 2—source data 5. Data underlying Appendix 4—figure 2C.
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Appendix 4—figure 2—source data 6. Data underlying Appendix 4—figure 2C.
Appendix 4—figure 2—source data 7. Data underlying Appendix 4—figure 2D.
Appendix 4—figure 2—source data 8. Data underlying Appendix 4—figure 2D.
Appendix 4—figure 2—source data 9. Data underlying Appendix 4—figure 2E.
Appendix 4—figure 2—source data 10. Data underlying Appendix 4—figure 2E.
Appendix 4—figure 2—source data 11. Data underlying Appendix 4—figure 2F.
Appendix 4—figure 2—source data 12. Data underlying Appendix 4—figure 2F.
Appendix 4—figure 3. Correlation between the HIV-1 viral load associated with an allele and
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the viral load associated with similar alleles. The early viral load set point associated with an
HLA class I allele (’Coefficient of Index Allele, x axis) was correlated with the coefficient of HLA
class I alleles with similar TCR binding (A), similar iKIR binding (B), similar activating KIR
binding (C), similar LILRB1 binding (D) and similar LILRB2 binding (E). All alleles in the cohort
of a sufficient frequency (N > 15) and with sufficient near alleles (N > 15 with 50% or more
similarity) were considered. The Spearman correlation coefficient (Rs) and corresponding P
value are reported in the title bar for each plot. Unlike HTLV-1 infection, and more in line with
expectation, the picture was mixed with no single interaction able to explain all HLA
associations. The only significant correlation was between the protection offered by an alleles
and the protection offered by alleles with similar LILRB2 binding (E). However, the correlation
was weak and there were plenty of alleles which did not conform to the pattern.
The online version of this article includes the following source data is available for figure 3:
Appendix 4—figure 3—source data 1. Data underlying Appendix 4—figure 3A.
Appendix 4—figure 3—source data 2. Data underlying Appendix 4—figure 3B.
Appendix 4—figure 3—source data 3. Data underlying Appendix 4—figure 3C.
Appendix 4—figure 3—source data 4. Data underlying Appendix 4—figure 3D.
Appendix 4—figure 3—source data 5. Data underlying Appendix 4—figure 3E.
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Appendix 4—figure 4. Correlation between the odds of HCV clearance associated with an
allele and the odds associated with similar alleles. The odds of spontaneous clearance of HCV
associated with an HLA class I allele (“Coefficient of Index Allele", x axis) was correlated with
the coefficient of HLA class I alleles with similar TCR binding (A), similar iKIR binding (B),
similar activating KIR binding (C), similar LILRB1 binding (D) and similar LILRB2 binding (E). All
alleles in the cohort of a sufficient frequency (N > 15) and with sufficient near alleles (N > 15
with 50% or more similarity) were considered. The Spearman correlation coefficient (Rs) and
corresponding P value are reported in the title bar for each plot. Unlike HTLV-1 infection, and
more in line with expectation, the picture was mixed with no single interaction able to explain
all HLA associations. The strongest positive correlation was seen for alleles with similar TCR
binding but the correlation is weak and not significant indicating that although the protection
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conferred by some alleles is attributable to TCR binding there are many alleles where the
protection is better explained by another interaction.
The online version of this article includes the following source data is available for figure 4:
Appendix 4—figure 4—source data 1. Data underlying Appendix 4—figure 4A.
Appendix 4—figure 4—source data 2. Data underlying Appendix 4—figure 4B.
Appendix 4—figure 4—source data 3. Data underlying Appendix 4—figure 4C.
Appendix 4—figure 4—source data 4. Data underlying Appendix 4—figure 4D.
Appendix 4—figure 4—source data 5. Data underlying Appendix 4—figure 4E.
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